Form 4: Provectus Biopharmaceuticals CEO Acquires 25.4 Million Stock Options
SEC Form 4
Provectus Biopharmaceuticals CEO, Edward Pershing, was granted 25.4 million stock options on December 2, 2024, which vest in three equal annual installments.
Summary
- Edward Pershing, CEO of Provectus Biopharmaceuticals, acquired 25,470,215 stock options on December 2, 2024.
- The options have an exercise price of $0.2862 per share.
- These options vest in three equal annual installments, starting on December 2, 2024.
- The options expire on December 2, 2034.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There is no indication of any negative sentiment.
Positives
- The grant of stock options to the CEO aligns his interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the CEO.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize executives and align their interests with shareholders.
Comparison to Industry Standards
- Stock option grants are a standard form of compensation for executives in the biotech industry.
- The vesting schedule of three years is also typical for such grants.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it incentivizes the CEO to increase the company's value.
- The CEO is incentivized to improve the company's performance to realize the value of the options.
Key Dates
| Date | Description |
|---|---|
| 12/02/2024 | Date of the stock option grant and the start of the vesting period. |
| 12/04/2024 | Date the form was signed. |
| 12/02/2034 | Expiration date of the stock options. |
Keywords
stock options, Provectus Biopharmaceuticals, CEO, Edward Pershing, equity, vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.